Is DiaMedica Therapeutics Inc. (DMAC) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.1% / 30% | 11.0% / 30% | 0.1% / 30% | N/A | ✓ HALAL |
| DJIM | 0.1% / 33% | 11.0% / 33% | 0.1% / 33% | N/A | ✓ HALAL |
| MSCI | 0.7% / 33% | 95.3% / 33% | 0.5% / 33% | N/A | ✗ NOT HALAL |
| S&P | 0.1% / 33% | 11.0% / 33% | 0.1% / 33% | N/A | ✓ HALAL |
| FTSE | 0.7% / 33% | 95.3% / 33% | 0.5% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -64.1% | |
| Return on Assets (ROA) | -38.3% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$22M |
| Free Cash Flow | -$22M |
| Total Debt | $340,000 |
| Debt-to-Equity | 0.5 |
| Current Ratio | 10.7 |
| Total Assets | $46M |
Price & Trading
| Last Close | $6.85 |
| 50-Day MA | $7.90 |
| 200-Day MA | $6.72 |
| Avg Volume | 212K |
| Beta | 1.1 |
|
52-Week Range
$3.19
| |
About DiaMedica Therapeutics Inc. (DMAC)
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction. The company also develops DM300, which is a recombinant human ulinastatin in the preclinical stage for the treatment of inflammatory diseases, such as acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is DiaMedica Therapeutics Inc. (DMAC) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), DiaMedica Therapeutics Inc. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is DiaMedica Therapeutics Inc.'s debt ratio?
DiaMedica Therapeutics Inc.'s debt ratio is 0.1% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.7%.
What are DiaMedica Therapeutics Inc.'s key financial metrics?
DiaMedica Therapeutics Inc. has a market capitalization of $354M. Return on equity stands at -64.1%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.